ADCs’ recent resurgence is just the beginning

Breakthroughs in ADC engineering are creating a comeback story for the modality, and a recent increase in ADC deals highlights industry’s growing enthusiasm.

After a bumpy start, in which only three antibody-drug conjugates (ADCs) were approved in the 17 years following the field’s first approval in 2000, the pace of ADC advancement is picking up. Not only have there been a recent flurry of approvals, with eight in the past three years, but an uptick in deal activity suggests the modality is quickly becoming strategically important for a wide swath of companies working in oncology...